Articles Referencing STML
Weekly recap: Most January pricings since 2006, Zoetis surges in debut
2/1/2013, 5:13 pm from Renaissance Capital in News Headlines, IPOs
After last week's five deals, January finished the month with 12
pricings, making it the second most active January in the past
decade, trailing only the 15 pricings in January 2006.... Read >>
Biotech Stemline Therapeutics prices upsized IPO at $10, the low end of the range
1/28/2013, 9:09 pm from Renaissance Capital in News Headlines, IPOs
Stemline Therapeutics, a biotech developing treatments that
target cancer stem cells and tumor bulk, raised $33 million by
offering 3.3 million shares (1.0 million more than expected) at
$10,... Read >>
5 US IPOs planned for the week of Jan 28
1/28/2013, 7:00 am from Renaissance Capital in News Headlines, IPOs
The following IPOs are expected to price this week : Gladstone Land ( LAND ), a externally
managed REIT planning to acquire agricultural real estate, plans to
raise $50 million by... Read >>
Stemline Therapeutics increases proposed IPO deal size
1/9/2013, 11:01 am from Renaissance Capital in News Headlines, IPOs
Stemline Therapeutics, a biotech developing treatments that
target cancer stem cells and tumor bulk, raised the proposed deal
size for its upcoming IPO on Wednesday. The New York,... Read >>
Stemline Therapeutics postpones IPO
8/7/2012, 9:55 am from Renaissance Capital in News Headlines, IPOs
Stemline Therapeutics, a biotech developing treatments that
target cancer stem cells and tumor bulk, postponed its IPO on
Tuesday. The New York, NY-based company had been planning to raise
$42... Read >>
4 US IPOs planned for the week of Jul 30
7/30/2012, 8:00 am from Renaissance Capital in News Headlines, IPOs
The following IPOs are expected to price this week : Eloqua ( ELOQ ), which provides
on-demand software to automate marketing and sales initiatives,
plans to raise $84 million by... Read >>
Stemline Therapeutics set terms for $42 million US IPO
7/20/2012, 9:44 am from Renaissance Capital in News Headlines, IPOs
Stemline Therapeutics, a biotech developing treatments that
target cancer stem cells and tumor bulk, announced terms for its
IPO on Friday. The New York, NY-based company plans to raise... Read >>